sever
acut
respiratori
syndrom
sar
emerg
human
diseas
detail
phylogenet
analysi
epidemiolog
studi
suggest
sar
coronaviru
sarscov
origin
anim
spike
glycoprotein
identifi
major
target
protect
immun
contain
region
target
neutral
antibodi
domain
previous
character
panel
neutral
human
monoclon
antibodi
mab
major
epitop
recogn
mab
remain
unknown
method
present
studi
gener
neutral
escap
mutant
studi
effect
neutral
escap
mutat
human
anim
receptor
usag
well
vitro
vivo
fit
result
distinct
partial
overlap
set
amino
acid
identifi
critic
bind
mab
differenti
neutral
profil
also
identifi
possibl
interact
domain
sarscov
glycoprotein
final
show
escap
neutral
usual
attenu
sarscov
infect
conclus
data
provid
mechan
overcom
neutral
escap
use
broadli
crossreact
cocktail
crossneutr
mab
recogn
residu
within
receptorbind
domain
critic
viru
replic
virul
sever
studi
shown
sarscov
spike
glycoprotein
bind
angiotensinconvert
enzym
receptor
major
compon
protect
immun
contain
domain
target
neutral
antibodi
previou
studi
gener
character
panel
human
monoclon
antibodi
mab
neutral
one
multipl
homolog
heterolog
sarscov
glycoprotein
variant
mab
could
categor
differ
neutral
profil
basi
abil
neutral
isogen
sarscov
bear
differ
human
zoonot
glycoprotein
mab
group
iiii
neutral
human
strain
zoonot
strain
group
vi
compris
mab
could
neutral
human
zoonot
sarscov
strain
test
vitro
vivo
demonstr
mab
attract
candid
prophylact
treatment
prevent
laboratoryacquir
infect
well
zoonot
introduct
howev
escap
neutraliza
tion
concern
develop
mab
therapeut
purpos
present
studi
gener
neutral
escap
mutant
panel
human
mab
use
structur
analysi
crossneutr
assay
sever
distinct
set
residu
critic
neutral
identifi
novel
site
outsid
receptorbind
domain
rbd
like
involv
receptor
interact
addit
effect
mutat
fit
virul
sarscov
determin
vitro
vivo
data
identifi
subset
compat
cocktail
human
mab
could
serv
potenti
therapeut
agent
laboratori
exposur
andor
new
sarscov
outbreak
set
recombin
icurbani
ichc
deriv
escap
mutant
propag
vero
cell
describ
elsewher
delay
brain
tumor
dbt
cell
stabli
express
human
h
civet
c
isol
flow
cytometri
describ
elsewher
growth
curv
perform
inocul
vero
cell
cultur
differ
virus
multipl
infect
moi
h
cell
overlaid
medium
viru
sampl
obtain
variou
time
point
infect
store
viral
titer
determin
plaqu
assay
describ
elsewher
escap
mutant
analysi
human
mab
sarscov
gener
describ
elsewher
neutralizationresist
sarscov
mutant
gener
describ
elsewher
brief
pfu
icurbani
incub
mg
neutral
mab
ml
media
h
inocul
onto
vero
cell
presenc
respect
mab
concentr
isol
use
gener
neutral
escap
mutant
mab
sever
attempt
gener
escap
mutant
antibodi
use
icurbani
prove
unsuccess
develop
cytopath
effect
monitor
h
progeni
virus
harvest
mab
treatment
repeat
addit
passag
passag
virus
plaqu
purifi
presenc
mab
neutralizationresist
virus
isol
experi
perform
duplic
glycoprotein
gene
individu
plaqu
experi
sequenc
describ
elsewher
neutral
titer
wildtyp
mabresist
virus
determin
describ
elsewher
comput
model
rbd
interact
crystal
structur
coordin
sarscov
rbd
interact
receptor
protein
data
bank
code
chain
chain
e
use
templat
map
locat
amino
acid
chang
identifi
escap
mutant
mous
infect
femal
balbcbi
mice
age
month
obtain
nation
institut
age
intranas
inocul
pfu
icurbani
escap
mutant
pfu
spectiv
escap
mutant
viru
volum
describ
elsewher
mice
weigh
daili
day
infect
lung
remov
frozen
determin
viral
titer
histopatholog
chang
describ
elsewher
experiment
protocol
review
approv
institut
anim
care
use
committe
univers
north
carolina
chapel
hill
icurbani
isol
use
gener
neutral
escap
mutant
basi
neutral
pattern
across
group
select
group
mab
group
ii
mab
group
iii
mab
group
iv
mab
group
vi
broadli
crossneutr
mab
import
escap
mutant
contain
singl
amino
acid
chang
wherea
escap
mutant
contain
amino
acid
chang
posit
tabl
escap
mutant
contain
singl
chang
wherea
escap
mutant
contain
chang
ident
previous
shown
use
glycoprotein
earlyphas
isol
interest
sever
mab
escap
mutant
differ
neutral
group
amino
acid
chang
common
tabl
amino
acid
chang
associ
neutral
escap
mutat
previous
shown
decreas
neutral
efficaci
mab
group
mab
group
iv
mab
group
vi
mab
select
escap
mutant
virus
amino
acid
chang
posit
final
gener
mab
neutral
escap
variant
use
mab
unsuccess
even
sever
attempt
use
icurbani
isol
howev
use
ichc
isol
mab
neutral
escap
mutant
isol
contain
singl
amino
acid
mutat
posit
result
either
chang
crossneutr
mab
neutral
escap
mutant
identif
mutat
associ
neutral
escap
yield
complex
set
overlap
nearli
overlap
mutat
within
rbd
suggest
escap
mutant
select
antibodi
may
provid
resist
neutral
use
human
mab
consequ
examin
crossneutr
pattern
escap
mutant
use
panel
select
mab
figur
neutral
efficaci
group
mab
ablat
chang
present
respect
escap
mutant
also
could
neutral
virus
contain
mutat
figur
neutral
efficaci
group
ii
mab
ablat
escap
mutant
except
mutant
figur
neutral
efficaci
group
iii
mab
affect
amino
acid
chang
chang
select
respect
escap
mutant
contrast
neutral
group
iii
mab
ablat
respect
escap
mutat
well
mutat
figur
mab
neutral
escap
mutant
gener
group
iv
mab
contain
amino
acid
chang
locat
close
togeth
surprisingli
neutral
efficaci
mab
similar
figur
final
group
vi
mab
previous
identifi
crossneutr
human
zoonot
sarscov
isol
unaffect
amino
acid
chang
natur
occur
sarscov
epidem
mab
affect
mutat
present
respect
neutral
escap
mutant
eg
figur
neutral
affect
amino
acid
chang
surpris
mab
select
ident
mutant
well
mab
select
mutat
affect
amino
acid
chang
none
amino
acid
chang
gener
escap
mutant
affect
neutral
efficaci
structur
map
amino
acid
critic
neutral
structur
sarscov
rbd
complex
recent
resolv
allow
us
map
locat
amino
acid
chang
onto
rbd
structur
previous
shown
amino
acid
rbd
critic
neutral
mab
locat
side
rbd
loop
direct
contact
receptor
figur
interest
although
mab
recogn
distinct
antigen
group
base
neutral
profil
isogen
virus
variant
glycoprotein
locat
amino
acid
chang
associ
neutral
escap
map
within
figur
unfortun
locat
amino
acid
alter
downstream
rbd
upstream
heptad
repeat
region
therefor
structur
inform
avail
chang
like
part
influenc
present
distinct
epitop
recogn
mab
belong
group
iii
figur
neutral
crossneutr
mab
affect
mutat
gener
mab
crossneutr
data
suggest
amino
acid
chang
associ
mab
neutral
escap
uniqu
separ
escap
mutant
figur
effect
glycoprotein
mutat
vitro
growth
urbani
glycoprotein
rbd
critic
dock
entri
engag
receptor
one
neutral
escap
mutat
either
directli
adjac
within
key
contact
residu
site
encod
rbd
posit
may
interfer
bind
neutral
escap
virus
grew
effici
vero
cell
reach
compar
peak
titer
pfuml
h
infect
figur
replic
virus
delay
earli
infect
shown
reduct
titer
h
infect
compar
wildtyp
icurbani
except
escap
mutant
chang
analysi
varianc
p
similar
trend
seen
dbt
cell
express
molecul
figur
growth
dbt
cell
express
molecul
affect
amino
acid
chang
test
virus
except
mutant
reach
vi
e
test
abil
neutral
escap
mutant
start
concentr
mab
select
show
reduct
neutral
least
dilut
mab
start
concentr
use
follow
mgml
mgml
mgml
mgml
mgml
mgml
mgml
mgml
mgml
mgml
mgml
describ
materi
method
mab
dilut
viru
neutral
plot
error
bar
denot
standard
deviat
p
compar
icurbani
wt
analysi
varianc
peak
titer
pfuml
delay
h
infect
replic
compar
icurbani
figur
import
h
infect
escap
mutant
viru
chang
show
reduct
titer
compar
icurbani
analysi
varianc
sugp
gest
escap
mutat
may
alter
viru
fit
dbt
cell
express
potenti
hamper
viru
persist
anim
reservoir
mutat
within
glycoprotein
sarscov
potenti
alter
morbid
mortal
test
possibl
balbc
mice
inocul
either
wildtyp
icurbani
respect
neutral
escap
mutant
condit
icurbani
result
phenotyp
weight
loss
interest
although
chang
attenu
effect
vitro
growth
differ
could
detect
weight
loss
associ
chang
associ
icurbani
isol
figur
contrast
neutral
escap
virus
chang
attenu
infect
mice
lose
weight
day
infect
wherea
virus
amino
acid
chang
complet
attenu
age
anim
figur
viral
titer
lung
infect
anim
day
infect
complet
correl
weight
loss
observ
elsewher
mutant
viru
grew
titer
compar
icurbani
pfug
figur
howev
mutant
viru
titer
significantli
reduc
log
respect
compar
icurbani
titer
agreement
data
mutat
previous
gener
also
complet
attenu
age
mice
data
shown
mutant
use
strain
associ
neutral
escap
mab
complet
attenu
age
mice
loss
weight
wherea
wildtyp
mice
lost
weight
day
infect
mice
die
figur
interest
differ
viru
titer
observ
day
infect
wildtyp
neutral
escap
mutant
figur
agreement
observ
weight
loss
anim
fect
lethal
strain
day
infect
necrot
bronchiol
could
observ
lung
mice
mark
loss
andor
attenu
bronchiolar
epithelium
also
note
figur
find
accompani
widespread
injuri
alveolar
parenchyma
histopatholog
injuri
gasexchang
region
lung
consist
diffus
alveolar
damag
interstiti
edema
hyalin
membran
format
interest
anim
infect
neutral
escap
mutant
gener
crossneutr
mab
minim
alveol
present
pulmonari
parenchyma
day
infect
hyalin
membran
observ
figur
neutral
antibodi
shown
import
recoveri
protect
infecti
diseas
howev
high
mutat
rate
heterogen
virus
major
problem
develop
therapeut
mab
especi
mab
human
virus
emerg
heterogen
pool
circul
anim
reservoir
knowledg
effect
escap
mutat
human
mab
acut
infect
human
epidem
zoonot
strain
emerg
viru
rigor
investig
goal
present
studi
character
antibodytarget
specif
larg
panel
neutral
human
mab
identifi
residu
critic
neutral
sarscov
isol
escap
mutant
effect
mutat
crossneutr
receptor
usag
vitro
vivo
replic
determin
goal
identifi
compat
candid
cocktail
broadspectrum
neutral
antibodi
therapeut
treatment
futur
sarscov
epidem
identifi
presenc
sever
critic
residu
associ
neutral
escap
mab
show
overlap
addit
show
mutat
associ
mab
neutral
escap
also
affect
kinet
replic
vitro
degre
pathogen
mice
mice
intranas
inocul
pfu
icurbani
strain
neutral
escap
mutant
b
pfu
strain
neutral
escap
mutant
c
ml
phosphatebuff
salin
pb
c
bodi
weight
infect
mice
measur
daili
basi
per
group
weight
n
p
chang
express
mean
percentag
chang
infect
anim
rel
initi
weight
day
b
lung
tissu
harvest
infect
mice
day
b
infect
assay
infecti
viru
describ
materi
method
tissu
sampl
mice
analyz
time
point
error
bar
denot
standard
deviat
compar
icurbani
wild
type
p
wt
analysi
varianc
mab
monoclon
antibodi
sarscov
excel
model
system
studi
develop
therapeut
antibodi
emerg
viru
sarscov
like
rna
virus
high
mutat
rate
import
adapt
chang
environ
creat
crossspeci
transmiss
use
panel
recombin
virus
bear
differ
glycoprotein
human
epidem
anim
strain
previous
character
panel
human
mab
describ
distinct
neutral
profil
suggest
presenc
sever
put
conform
epitop
studi
perform
detail
analysi
residu
critic
neutral
differ
human
mab
differenti
neutral
anim
human
strain
four
residu
posit
map
within
rbd
structur
associ
escap
neutral
mab
differ
neutral
profil
suggest
overlap
antigen
site
although
mabrbd
cocrystal
studi
necessari
determin
complex
architectur
orient
rbdneutral
epitop
data
suggest
subtl
chang
around
escap
mutat
site
affect
antibodi
bind
neutral
fact
experiment
structur
data
avail
support
hypothesi
overlap
epitop
sarscov
rbd
recogn
mab
display
distinct
neutral
profil
escap
mutant
analysi
assist
identif
figur
lung
patholog
find
balbc
mice
infect
wildtyp
wt
escap
mutant
kill
day
inocul
sign
inflamm
virusinduc
lung
patholog
find
evid
wtinfect
mice
day
infect
necrot
bronchiol
accompani
widespread
injuri
alveolar
parenchyma
consist
diffus
acut
alveol
interstiti
edema
congest
alveolar
septa
around
small
blood
vessel
scatter
microthrombi
septal
capillari
hyalin
membran
format
contrast
mice
infect
neutral
escap
mutant
show
inflamm
hyalin
membran
format
antigen
site
sever
virus
includ
rhinoviru
sarscov
previous
use
identifi
import
neutral
sarscov
mab
structur
mab
complex
sarscov
rbd
describ
elsewher
mab
mainli
recogn
loop
protrud
rbd
surfac
compet
bind
rbd
epitop
includ
amino
acid
residu
distant
epitop
competit
like
occur
steric
hindranc
mab
mab
found
interact
residu
sarscov
rbd
residu
particular
interest
mutat
residu
complet
abolish
bind
interest
mutat
residu
also
found
affect
neutral
efficaci
one
group
iii
mab
describ
present
studi
suggest
mab
recogn
ident
overlap
epitop
hypothes
elsewher
crossneutr
data
suggest
associ
residu
group
residu
locat
recent
anoth
studi
demonstr
associ
amino
acid
chang
domain
sarscov
affect
neutral
current
structur
complet
sarscov
glycoprotein
bound
receptor
elucid
therefor
map
effect
longrang
amino
acid
chang
outsid
rbd
global
glycoprotein
structur
possibl
howev
data
suggest
domain
glycoprotein
commun
rbd
may
even
interact
physic
higherord
structur
glycoprotein
shown
coronavirus
import
domain
outsid
rbd
target
neutral
mab
includ
amino
acid
although
clear
whether
domain
associ
rbd
previou
work
also
implic
chang
posit
affect
neutral
mab
rbd
bind
although
gener
neutral
escap
mutant
help
tool
identif
residu
critic
neutral
gener
compromis
use
singl
mab
prophylaxi
treatment
howev
amino
acid
chang
within
sarscov
glycoprotein
affect
neutral
also
dramat
effect
fit
virul
viru
previou
studi
show
singl
mutat
posit
outsid
rbd
zoonot
glycoprotein
gene
associ
develop
cytopath
effect
cell
cultur
addit
introduct
amino
acid
chang
sarscov
glycoprotein
result
lethal
infect
age
mice
current
studi
show
clear
effect
vitro
replic
sever
differ
escap
amino
acid
mutat
mani
escap
mutant
grew
similar
titer
initi
delay
growth
observ
mutat
like
mediat
reduc
affin
rbd
receptor
result
delay
entri
escap
mutant
also
influenc
abil
viru
grow
cell
express
suggest
escap
virus
may
ineffici
maintain
anim
reservoir
encouragingli
mani
escap
mutat
also
clear
effect
vivo
pathogenesi
use
age
mous
model
although
mutat
residu
affect
vivo
pathogenesi
mutat
either
partial
complet
attenu
sarscov
infect
age
mice
decreas
virul
neutral
escap
mutant
also
observ
influenza
virus
coincid
reduc
affin
mutant
ha
receptor
given
delay
growth
mani
escap
mutant
cell
express
anticip
would
attenu
human
addit
unsuccess
isol
mutant
resist
sequenti
gener
escap
variant
use
differ
mab
sever
attempt
rescu
viru
escap
mutant
incub
neutral
mab
presenc
origin
mab
unsuccess
unpublish
data
therefor
cocktail
potent
broadli
crossneutr
mab
like
one
describ
elsewher
overcom
neutral
escap
provid
protect
diseas
laboratori
accid
zoonot
introduct
focal
outbreak
diseas
conclus
data
support
hypothesi
multipl
overlap
neutral
epitop
exist
within
rbd
sarscov
glycoprotein
cluster
escap
mutat
affect
neutral
mab
differ
neutral
profil
residu
locat
associ
epitop
involv
residu
suggest
longrang
interact
within
sarscov
glycoprotein
show
neutral
escap
come
cost
reduc
viral
fit
propos
develop
broadli
crossneutr
mab
cocktail
overcom
gener
escap
variant
propos
cocktail
mab
particularli
robust
mab
individu
neutral
broad
panel
human
zoonot
sarscov
variant
select
escap
mutat
differ
site
rbd
escap
mutant
sever
attenu
age
anim
